114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination

BACKGROUND: For the first time, we present data describing vaccine efficacy (VE), immunogenicity persistence and safety up to approximately 10 years after primary vaccination against HZ with RZV. We have previously shown that RZV demonstrated high VE against HZ in adults ≥ 50 years of age (YOA) part...

Descripción completa

Detalles Bibliográficos
Autores principales: Strezova, Ana, Diez-Domingo, Javier, Shawafi, Kamal Al, Tinoco, Juan Carlos, Shi, Meng, Pirrotta, Paola, Mwakingwe-Omari, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172706/
http://dx.doi.org/10.1093/ofid/ofac492.192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172706/
http://dx.doi.org/10.1093/ofid/ofac492.192

Ejemplares similares